Garsorasib

Garsorasib is a pharmaceutical drug used for cancer treatment. It is a selective inhibitor of the enzyme KRAS that has the G12C mutation.^[1][2]

Trade names安方宁

Other namesD-1553

Legal status

• Rx in China

CAS Number

• 2559761-14-5

Quick facts Clinical data, Trade names ...

Garsorasib

Clinical data
Trade names	安方宁
Other names	D-1553
Legal status
Legal status	Rx in China
Identifiers
IUPAC name 7-(2-Amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoropyrido[2,3-d]pyrimidin-2-one
CAS Number	2559761-14-5
PubChem CID	155332312
ChemSpider	115010420
UNII	P491NE9G6Z
ChEMBL	ChEMBL5095066
Chemical and physical data
Formula	C32H32F2N8O2
Molar mass	598.659 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H]1CN([C@H](CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)N)C5=C(N=CN=C5C6CC6)C7CC7
InChI InChI=1S/C32H32F2N8O2/c1-4-24(43)40-13-17(3)41(14-16(40)2)30-20-12-22(34)28(25-21(33)6-5-7-23(25)35)38-31(20)42(32(44)39-30)29-26(18-8-9-18)36-15-37-27(29)19-10-11-19/h4-7,12,15-19H,1,8-11,13-14,35H2,2-3H3/t16-,17+/m1/s1 Key:DKFRWZJCNPETGI-SJORKVTESA-N

Close

In China, it is approved for the treatment of advanced non-small cell lung cancer (NSCLC) carrying the KRAS G12C mutation in patients who have received at least one systemic treatment.^[3]